Metabolic syndrome and non-alcoholic fatty liver disease
Journal Title: Annals of Hepatology - Year 2009, Vol 8, Issue 1
Abstract
The development of nonalcoholic fatty liver disease (NAFLD) is strongly associated with the metabolic syndrome as reflected by the fact that approximately 90% of the patients with NAFLD have more than one feature of metabolic syndrome and about 33% have three or more criteria. The physiopathology, epidemiology and therapeutic considerations of the disease are reviewed here. Lipotoxicity plays a predominant role in the pathophysiology of both entities. It leads to accumulation of triglycerides in the liver as a result of an imbalance among the uptake, synthesis, export, and oxidation of fatty acids. Both conditions are very common in Mexico. Using the Adult Treatment Panel diagnostic criteria, the 1994 prevalence of the metabolic syndrome was 26.6%.Although the prevalence of NAFLD is not known, but it can be estimated from the prevalence of obesity (30%). Since NAFLD is found in over two thirds of the obese subjects, this condition may exist in 20% of the adult population. The treatment of both conditions should be based in an integral approach, including the adoption of a healthy lifestyle, weight loss and may be pharmacotherapy. In summary, NAFLD is the hepatic expression of the metabolic syndrome. The study and treatment of these disorders could not be viewed as separate issues.
Authors and Affiliations
Paloma Almeda-Valdés, Daniel Cuevas-Ramos, Carlos Aguilar-Salinas
Keywords
Related Articles
- EP ID EP77839
- DOI -
- Views 136
- Downloads 0
Mean platelet volume: a useful predictor of ascitic fluid infection in cirrhotic patients?
A Dynamic Model for Predicting Outcome in Patients with HBV Related Acute-On-Chronic Liver Failure
Introduction and aim. Accurately predicting the prognosis of individual patient is crucial in the management of ACLF. We aimed to establish a specific prognostic model for HBV-related ACLF patients treated with nucleosid...
Current and future treatment options for HCV
Aim of antiviral therapy of patients with chronic hepatitis C is the sustained elimination of the hepatitis C virus (HCV). The standard of care (SOC) is peginterferon alfa-2a/-2b with ribavirin for 48 weeks or 24 weeks i...
NASH and cryptogenic cirrhosis: A histological analysis†
Introduction. Epidemiological studies indicate that nonalcoholic steatohepatitis (NASH) is a common cause of cirrhosis described as ‘cryptogenic’. To address this from a histological perspective and to examine the signif...
Predictors and impacts of hospital readmissions following liver transplantation
While liver transplantation is the definitive therapy for end stage liver disease, it remains a major procedure, with many potential complications. Hospital readmissions after the initial hospitalization for liver trans...